Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

14 articles for KD Freeman-Cook

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists.

Pfizer

Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylase.

Pfizer

Design of selective, ATP-competitive inhibitors of Akt.

Pfizer

Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2.

Pfizer

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.

Pfizer

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer.

Pfizer

Potent, selective pyrimidinetrione-based inhibitors of MMP-13.

Pfizer

2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH

Bayer Aktiengesellschaft

Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors

Incyte

Quinoline compounds as modulators of RAGE activity and uses thereof

TBA

Dihydropyrrolopyridine inhibitors of ROR-gamma

Vitae Pharmaceuticals

Conjugate comprising a neurotensin receptor ligand and use thereof

3B Pharmaceuticals

The preparation, in vitro screening and molecular docking of symmetrical bisquaternary cholinesterase inhibitors containing a but-(2E)-en-1,4-diyl connecting linkage.

University of Defence

Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors

Bioaxone Biosciences